Bahram Valamehr - 06 Jul 2022 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Role
Chief R&D Officer
Signature
/s/ Cindy Tahl, as Attorney-in-Fact
Issuer symbol
FATE
Transactions as of
06 Jul 2022
Net transactions value
-$235,809
Form type
4
Filing time
07 Jul 2022, 16:04:11 UTC
Previous filing
15 Mar 2022
Next filing
08 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FATE Common Stock Options Exercise $9,680 +2,000 +1.1% $4.84 181,834 06 Jul 2022 Direct F1
transaction FATE Common Stock Options Exercise $15,949 +5,842 +3.2% $2.73 187,676 06 Jul 2022 Direct F1
transaction FATE Common Stock Sale $235,809 -7,842 -4.2% $30.07* 179,834 06 Jul 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FATE Stock Option (Right to Buy) Options Exercise $9,680 -2,000 -19% $4.84 8,704 06 Jul 2022 Common Stock 2,000 $4.84 Direct F1, F3
transaction FATE Stock Option (Right to Buy) Options Exercise $15,949 -5,842 -16% $2.73 30,314 06 Jul 2022 Common Stock 5,842 $2.73 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2020.
F2 Represents the weighted average sale price of the shares sold ranging from $30.00 to $30.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range set forth in footnote 2.
F3 This option is fully vested.